Navigation Links
IFRS Information - First Half of 2007
Date:9/13/2007

illion (2006: $12.2 million). The increase in finance costs in 2007 over 2006 follows the acquisition of New River which was partly funded by $1.3 billion of term loans, utilized under Shire's $2.3 billion banking facility. These term loans were subsequently partially repaid using the proceeds from Shire's 2.75% convertible bond issued in May 2007. The remaining $200 million of the term loans was also repaid during the six months to June 30, 2007. Finance costs for the six months to June 30, 2007 include a $7.9 million write-off of deferred financing costs following the repayment of these term loans. Finance costs relating to the convertible bonds, representing interest expense, amortized discount and issue costs totaled $10.8 million for the six months to June 30, 2007.

In the six months to June 30, 2007 and 2006 finance costs included a provision for interest, which may be awarded by the Court in respect of amounts due to those ex-TKT shareholders who have requested appraisal of the acquisition consideration payable for their TKT shares. The original trial date for the appraisal rights litigation was set for April 23, 2007, but this trial date has since been postponed to May 2008.

Share of post tax profits from associates and joint ventures

Profits of $1.2 million were recorded for the six months to June 30, 2007 (2006: $4.3 million). This comprised profits of $3.1 million from the 50% share of the antiviral commercialization partnership with GSK in Canada (2006: $3.2 million), offset by losses of $1.9 million being Shire's share of losses in the GeneChem and EGS Healthcare Funds (2006: profit of $1.1 million).

Taxation

The effective rate of tax for the six months to June 30, 2007 was 77% (2006: 32%). The effective rate of tax in the six months to June 30, 2007 has increased over the six months to June 30, 2006 as a result of the inclusion in 2007 of non-deductible goodwill impairment charges totaling $80.9 million (2006: $nil). Exclu
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Imaging and Analysis of DIGE Product Information Sheet, Rev B
2. Study affirms information technology-productivity link
3. TrafficCast integrates new information source
4. Rote education fails the Information Age
5. Weather information companies launch data product
6. TeraMedica launches information manager
7. Global information firm reaches diverse markets
8. Preparing for avian flu with information technology
9. Businesses cant hide personal information losses, theft
10. S.C. Johnson lands in No. 2 spot in Information Week 500 list
11. Crate and Barrel deploys Firstlogics Information Quality Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ... and Chief Executive Officer, will present at the Rodman & ... New York on Tuesday, Sept. 9, 2014 ... archived webcast of the presentation will be accessible by visiting ... Events" section. About Oncothyreon ...
(Date:9/2/2014)... , September 2, 2014 ... BioData,s research and lab management services  BioData, ... service, is pleased to announce the appointment of ... most recently served as VP Marketing and Business Development ... science research and clinical applications. Previously, Culot ...
(Date:8/31/2014)... Aug. 31, 2014 Wockhardt Limited today announces ... in Anti-Infective research when two of its drugs, WCK ... Disease Product (QIDP) status from U.S. Food & Drug ... act against pathogens which have a high degree of ... Centre for Disease Control (a top U.S. government health ...
(Date:8/29/2014)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage ... and difficult to manufacture proteins including biosimilar therapeutics, ... results for the second quarter ended June 30, ... our initial public offering, we have the capital ... derived from our proprietary protein expression platform," stated ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8
... Inc. (Nasdaq: IDEV ) today announced that ... Food and Drug Administration (FDA) for,VALSTAR(R). VALSTAR, a ... only product approved by the FDA for therapy ... the,urinary bladder. VALSTAR was removed from the ...
... Extracranial Resources Benefits Baltimore ... Area and ... Cancer Center at Johns Hopkins Medicine is adding an Elekta,Synergy(R) S ... Johns Hopkins aims to fight cancer with,both intracranial and extracranial resources ...
... Balance of Year, SAN DIEGO, Aug. 17 ... Noble Financial Equity,Conference at 11:30 a.m. EDT on Tuesday, ... South Carolina. William Spencer, Imagenetix,s Chief Executive Officer ... and prospects for the,Company. Commenting on the prospects, Mr. ...
Cached Biology Technology:Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 2Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 3Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy 4Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup 2Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup 3Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007 2
(Date:9/2/2014)... hot oven, you rapidly pull your hand away. Although ... and responding to such painful stimuli, they are still ... made a surprising discovery about the role of a ... built a structural model of the molecule. These discoveries, ... help direct new strategies to treat pain in people. ...
(Date:9/1/2014)... of research shows an association between TV viewing and ... a new Cornell University study points out that not ... people to eat twice as much as other programs! ... while snacking your mouth will see more action too!" ... article just published in the Journal of the ...
(Date:9/1/2014)... of the U.S. diet showed some modest improvement in ... reduction in the consumption of unhealthy trans fats, but ... rich and the poor. , , An unhealthy diet ... cancers. Eating a healthy diet is an important part ... population trends in diet quality is important because it ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Can action movies make you fat? 2Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
... picture in this kind of article , A detailed ... in activating the Epstein Barr Virus in human cells has ... Laboratory (EMBL) and the Institut de Virologie Mol├ęculaire et Structurale ... in Grenoble. , Like Sleeping Beauty, the Epstein Barr Virus ...
... leading plant science centre have uncovered a gene that could ... able to cope with the changing world climate. Researchers funded ... the John Innes Centre in Norwich have identified the gene ... changes in the length of the day. This is key ...
... avian flu conference last fall believe there is little chance ... enough vaccine or antiviral medication to stop a bird flu ... be spread easily from human to human, according to a ... of the survey will be published in the June 2006 ...
Cached Biology News:Waking a sleeping virus 2Growing crops to cope with climate change 2Medical experts: US unlikely to have enough vaccines to stop avian flu 2
...
... DEPC-treated Water is suitable for ... prepared by incubating with 0.1% ... to remove the DEPC.DNase/RNase-Free Distilled ... use in all molecular biology ...
IHC detection kit for BrdU in cells and tissues...
Immunogen: Human Respiratory Syncytial Virus (RSV) and Bovine Respiratory Syncytial Virus (BRSV) Fusion protein Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: